Intellia Therapeutics (NASDAQ:NTLA) – Leerink Swann issued their Q4 2018 earnings per share (EPS) estimates for Intellia Therapeutics in a report issued on Wednesday, March 14th, Zacks Investment Research reports. Leerink Swann analyst J. Schwartz expects that the company will post earnings of ($0.46) per share for the quarter. Leerink Swann currently has a “Outperform” rating on the stock.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.16). The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $8.84 million. Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. Intellia Therapeutics’s revenue for the quarter was up 19.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.31) EPS.
Several other equities analysts have also recently commented on the stock. TheStreet raised shares of Intellia Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 19th. BidaskClub cut shares of Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 21st. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, March 15th. JMP Securities began coverage on shares of Intellia Therapeutics in a research report on Thursday, March 8th. They set an “outperform” rating for the company. Finally, Barclays lifted their target price on shares of Intellia Therapeutics from $33.00 to $46.00 and gave the company an “overweight” rating in a research report on Wednesday, March 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Intellia Therapeutics has an average rating of “Buy” and a consensus price target of $34.83.
NASDAQ:NTLA traded down $1.41 during mid-day trading on Friday, hitting $20.45. 1,121,611 shares of the stock traded hands, compared to its average volume of 1,603,846. The stock has a market cap of $866.81, a P/E ratio of -10.88 and a beta of 2.83. Intellia Therapeutics has a 12-month low of $11.15 and a 12-month high of $35.99.
A number of institutional investors have recently modified their holdings of NTLA. Farallon Capital Management LLC purchased a new position in Intellia Therapeutics during the 4th quarter valued at $21,911,000. ARK Investment Management LLC increased its position in Intellia Therapeutics by 269.2% during the 4th quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock valued at $26,430,000 after purchasing an additional 1,002,671 shares during the period. GMT Capital Corp purchased a new position in Intellia Therapeutics during the 3rd quarter valued at $8,214,000. Shellback Capital LP purchased a new position in Intellia Therapeutics during the 4th quarter valued at $2,343,000. Finally, Capital Advisors Inc. OK purchased a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $1,946,000. 57.10% of the stock is currently owned by institutional investors and hedge funds.
In other Intellia Therapeutics news, Director Jean Francois Formela sold 39,245 shares of the business’s stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The disclosure for this sale can be found here. Insiders own 12.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Intellia Therapeutics (NTLA) Forecasted to Earn Q4 2018 Earnings of ($0.46) Per Share” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/analysts-offer-predictions-for-intellia-therapeutics-incs-q4-2018-earnings-ntla.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.